Stephen A. Beers

This paper evaluates two TNFR2-targeting antibodies, showing ligand-blocking antibodies deplete T regs and reprogram myeloid cells, while agonists directly co-stimulate T and NK cells, both leading to anti-tumor effects.

This study shows that bispecific antibody architecture and TNFRSF target selection influence CD8+ T cell differentiation and anti-tumour immunity, with 4-1BB being the most effective target.